CCDC149

Across TCGA pan-cancer cohorts, CCDC149 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC149 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CCDC149 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC149 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, HNSC, and LAML are the cancer types where CCDC149 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.028	0.675	<.001	63	view →
HNSC	OS	Median	All	0.157	0.687	<.001	48	view →
LAML	DFS	Median	All	0.056	0.572	.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	All	0.950	0.634	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCDC149–ACC (DFS)

Open the ACC breakdown →